Acorah Software Products - Accounts Production 16.5.460 false true 31 January 2024 1 February 2023 false 1 February 2024 31 January 2025 31 January 2025 10665744 Mr KAUSHIK KANTILAL AMLANI iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 10665744 2024-01-31 10665744 2025-01-31 10665744 2024-02-01 2025-01-31 10665744 frs-core:ShareCapital 2025-01-31 10665744 frs-core:RetainedEarningsAccumulatedLosses 2025-01-31 10665744 frs-bus:PrivateLimitedCompanyLtd 2024-02-01 2025-01-31 10665744 frs-bus:AbridgedAccounts 2024-02-01 2025-01-31 10665744 frs-bus:SmallEntities 2024-02-01 2025-01-31 10665744 frs-bus:AuditExempt-NoAccountantsReport 2024-02-01 2025-01-31 10665744 frs-bus:SmallCompaniesRegimeForAccounts 2024-02-01 2025-01-31 10665744 frs-bus:Director1 2024-02-01 2025-01-31 10665744 frs-countries:EnglandWales 2024-02-01 2025-01-31 10665744 2023-01-31 10665744 2024-01-31 10665744 2023-02-01 2024-01-31 10665744 frs-core:ShareCapital 2024-01-31 10665744 frs-core:RetainedEarningsAccumulatedLosses 2024-01-31
Registered number: 10665744
MEDIC888 PHARMA LTD
Unaudited ABRIDGED Financial Statements
For The Year Ended 31 January 2025
MEDIC888 PHARMA LTD
Contents
Contents

| Page
--- | ---
Abridged Balance Sheet | 1—2
Notes to the Abridged Financial Statements | 3

Page 1
MEDIC888 PHARMA LTD
Abridged Balance Sheet
As At 31 January 2025
Abridged Balance Sheet
Registered number: 10665744

| 2025 | 2024
--- | --- | ---
| Notes | £ | £ | £ | £
CURRENT ASSETS
Cash at bank and in hand |  | 12,439 |  | 12,439 |
|  | 12,439 |  | 12,439 |
Creditors: Amounts Falling Due Within One Year |  | (17,317 ) |  | (17,317 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | (4,878 ) |  | (4,878 )
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | (4,878 ) |  | (4,878 )
NET LIABILITIES |  |  | (4,878 ) |  | (4,878 )
CAPITAL AND RESERVES
Called up share capital | 4 |  | 1 |  | 1
Profit and Loss Account |  |  | (4,879 ) |  | (4,879 )
SHAREHOLDERS' FUNDS |  |  | (4,878) |  | (4,878)

Page 1
Page 2
MEDIC888 PHARMA LTD
Abridged Balance Sheet (continued)
As At 31 January 2025
For the year ending 31 January 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
All of the company's members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet for the year end 31 January 2025 in accordance with section 444(2A) of the Companies Act 2006.
On behalf of the board

Mr KAUSHIK KANTILAL AMLANI Director
03/10/2025

The notes on page 3 form part of these financial statements.
Page 2
Page 3
MEDIC888 PHARMA LTD
Notes to the Abridged Financial Statements
For The Year Ended 31 January 2025
Notes to the Abridged Financial Statements
1. General Information
MEDIC888 PHARMA LTD is a private company, limited by shares, incorporated in England & Wales, registered number 10665744 . The registered office is Bregroup, , Block 15-3,, Room 105d Bucknalls Bricket Wood, , Watford, England, , WD25 9NH.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
3. Average Number of Employees
Average number of employees, including directors, during the year was: NIL (2024: NIL)
- -
4. Share Capital

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 1 |  | 1

Page 3